Core Insights - ACA Pharma's China NPP Group Procurement Program aims to expedite access to orphan and clinically urgent drugs for Chinese patients, reducing the time frame from years to months through compliant fast-track pathways [1][2] Group NPP Access Options - The program offers two compliant access pathways: Direct Group NPP Procurement, which allows manufacturers to supply therapies directly to hospitals without NMPA registration or local clinical trials, and Macau Fast Registration, enabling 30–90 day registration in Macau for broader market access [2][3] 2026 Priority List - The 2026 China NPP Group Procurement Priority List is based on input from multiple stakeholders, reflecting hospital-driven demand for therapies that are unregistered or under-available in China [3][5] - The list includes high-priority categories such as pediatric neurology, oncology, and metabolic rare-disease therapies, with specific examples like CABOMETYX® and NITYR® highlighted [4][6] Global NPP Export Network - ACA Pharma leverages over 30 years of experience in global NPP export and distribution to deliver U.S. pediatric and orphan drug products to unregistered countries, allowing manufacturers to centralize operations while maintaining regulatory compliance [8] Real-World Evidence and Accelerated Approvals - Real-world evidence from early-access centers can support accelerated national approvals for pediatric orphan drugs and clinically urgent therapies, potentially within 3–6 months and 6–12 months, respectively [12] Comprehensive Commercialization Services - ACA Pharma provides end-to-end commercialization services, including registration, importation, warehousing, distribution, and promotion, supported by strong relationships with regulators and hospital groups across Greater China and Southeast Asia [13]

Core Insights - Exelixis, Inc. announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) against placebo in patients with previously treated advanced neuroendocrine tumors (NET) originating in the lungs or thymus [1] Group 1 - The data from the trial will be presented at the 2025 European Society for Medical Oncology Congress (ESMO) during the Monday Poster Session: Neuroendocrine Tumours on October 20, 2025, from 12:00 – 12 [1]